|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differentiating Crohn's disease from intestinal tuberculosis显示文摘Differentiating Crohn's disease(CD) and intestinal tuberculosis(ITB) has remained a dilemma for most of the clinicians in the developing world, which are endemic for ITB, and where the disease burden of inflammatory bowel disease is on the rise. Although, there are certain clinical(diarrhea/hematochezia/perianal disease common in CD; fever/night sweats common in ITB), endoscopic(longitudinal/aphthous ulcers common in CD; transverse ulcers/patulous ileocaecal valve common in ITB), histologic(caseating/confluent/large granuloma common in ITB; microgranuloma common in CD), microbiologic(positive stain/culture for acid fast-bacillus in ITB), radiologic(long segment involvement/comb sign/skip lesions common in CD; necrotic lymph node/contiguous ileocaecal involvement common in ITB), and serologic differences between CD and ITB, the only exclusive features are caseation necrosis on biopsy, positive smear for acid-fast bacillus(AFB) and/or AFB culture, and necrotic lymph node on cross-sectional imaging in ITB. However,these exclusive features are limited by poor sensitivity, and this has led to the development of multiple multi-parametric predictive models. These models are also limited by complex formulae, small sample size and lack of validation across other populations. Several new parameters have come up including the latest Bayesian meta-analysis, enumeration of peripheral blood T-regulatory cells, and updated computed tomography based predictive score. However, therapeutic anti-tubercular therapy(ATT) trial, and subsequent clinical and endoscopic response to ATT is still required in a significant proportion of patients to establish the diagnosis. Therapeutic ATT trial is associated with a delay in the diagnosis of CD, and there is a need for better modalities for improved differentiation and reduction in the need for ATT trial. | Saurabh Kedia Prasenjit Das Kumble Seetharama Madhusudhan Siddhartha Dattagupta Raju Sharma Peush Sahni Govind Makharia Vineet Ahuja | 2019 | World Journal of Gastroenterology2019，25，4： | 19 |
| 2 | The impact of performance-based compensation on misreporting显示文摘 | Natasha Burns Simi Kedia | 2005 | Journal of Financial Economics2005，，1： | 4 |
| 3 | Tehri水电大坝项目对非自愿移民健康的影响评估显示文摘水电大坝项目在提供电力 ,通过灌溉提高农业产量以及控制洪水泛滥 ,以提高人们福利为目标的方面有着巨大的潜力 .从蓄水而对居民进行迁移到在大坝、水库以及灌溉的渠道周围建设新的安置区为止 ,大坝的建设在许多方面对人们产生影响 .目前世界的移民政策主要针对土地及房屋补偿问题 ,并在某种程度上对受项目影响的人们提供基本的物质补偿 .然而 ,移民对于迁移人口以及居住于大坝、水库、沟渠周围人民的健康的影响没有得到应有的重视 .基于全球的移民项目以及北印度的Tehri大坝案例研究的基础上 ,研究了水电大坝对受影响居民的健康状况的影响这样一个全球性的具有挑战性的问题 . | Satish Kedia 魏静 陈绍军 | 2003 | 水利水电科技进展2003，23，2： | 3 |
| 4 | S-Nitroso-N-acetyl-L-cysteine ethyl ester(SNACET) and N-acetyl-L-cysteine ethyl ester(NACET)–Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H_2S and GSH suppliers and as antioxidants: Results and overview显示文摘S-Nitrosothiols or thionitrites with the general formula RSNO are formally composed of the nitrosyl cation(NOt) and a thiolate(RSà), the base of the corresponding acids RSH. The smallest S-nitrosothiol is HSNO and derives from hydrogen sulfide(HSH, H_2S). The most common physiological S-nitrosothiols are derived from the amino acid L-cysteine(Cys SH). Thus, the simplest S-nitrosothiol is S-nitroso-L-cysteine(Cys SNO). Cys SNO is a spontaneous potent donor of nitric oxide(NO) which activates soluble guanylyl cyclase to form cyclic guanosine monophosphate(c GMP). This activation is associated with multiple biological actions that include relaxation of smooth muscle cells and inhibition of platelet aggregation.Like NO, Cys SNO is a short-lived species and occurs physiologically at concentrations around 1 n M in human blood. Cys SNO can be formed from Cys SH and higher oxides of NO including nitrous acid(HONO)and its anhydride(N_2O_3). The most characteristic feature of RSNO is the S-transnitrosation reaction by which the NOtgroup is reversibly transferred to another thiolate. By this way numerous RSNO can be formed such as the low-molecular-mass S-nitroso-N-acetyl-L-cysteine(SNAC) and S-nitroso-glutathione(GSNO), and the high-molecular-mass S-nitrosol-L-cysteine hemoglobin(Hb Cys SNO) present in erythrocytes and S-nitrosol-L-cysteine albumin(Alb Cys SNO) present in plasma at concentrations of the order of 200 n M. All above mentioned RSNO exert NO-related biological activity, but they must be administered intravenously. This important drawback can be overcome by lipophilic charge-free RSNO.Thus, we prepared the ethyl ester of SNAC, the S-nitroso-N-acetyl-L-cysteine ethyl ester(SNACET), from synthetic N-acetyl-L-cysteine ethyl ester(NACET). Both NACET and SNACET have improved pharmacological features over N-acetyl-L-cysteine(NAC) and S-nitroso-N-acetyl-L-cysteine(SNAC), respectively,including higher oral bioavailability. SNACET exerts NO-related activities which can be utilized in the urogenital tract and in the cardiovascular system. NACET, with high oral bioavailability, is a strong antioxidant and abundant precursor of GSH, unlike its free acid N-acetyl-L-cysteine(NAC). Here, we review the chemical and pharmacological properties of SNACET and NACET as well as their analytical chemistry.We also report new results from the ingestion of S-[^(15) N]nitroso-N-acetyl-L-cysteine ethyl ester(S^(15) NACET) demonstrating the favorable pharmacological profile of SNACET. | Dimitrios Tsikas Kathrin S.Schwedhelm Andrzej Surdacki Daniela Giustarini Ranieri Rossi Lea Kukoc-Modun George Kedia Stefan ückert | 2018 | Journal of Pharmaceutical Analysis2018，8，1： | 3 |
| 5 | Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial显示文摘AIM To evaluate the role of oral curcumin in inducing clinical remission in patients with mild to moderate ulcerative colitis(UC).METHODS A prospective randomized double-blind placebo-controlled trial comparing the remission inducing effect of oral curcumin and mesalamine 2.4 g with placebo and mesalamine 2.4 g in patients of ulcerative colitis with mild to moderate severity was conducted from January 2003 to March 2005. The included patients received 1 capsule thrice a day of placebo or curcumin(150 mg) for 8 wk. Patients were evaluated clinically and endoscopically at 0,4 and 8 wk. The primary outcome was clinical remission at 8 wk and secondary outcomes were clinical response, mucosal healing and treatment failure at 8 wk. The primary analysis was intention to treat worst case scenario(ITT-WCS).RESULTS Of 300 patients with UC, 62 patients(curcumin: 29, placebo: 33) fulfilled the inclusion criteria and were randomized at baseline. Of these, 21 patients did not complete the trial, 41 patients(curcumin: 16, placebo: 25) finally completed 8 wk. There was no significant difference in rates of clinical remission(31.3% vs 27.3%, P = 0.75), clinical response(20.7% vs 36.4%, P = 0.18), mucosal healing(34.5% vs 30.3%, P = 0.72), and treatment failure(25% vs 18.5%, P = 0.59) between curcumin and placebo at 8 wk.CONCLUSION Low dose oral curcumin at a dose of 450 mg/d was ineffective in inducing remission in mild to moderate cases of UC. | Saurabh Kedia Vikram Bhatia Sandeep Thareja Sushil Garg Venigalla Pratap Mouli Sawan Bopanna Veena Tiwari Govind Makharia Vineet Ahuja | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，2： | 2 |
| 6 | Institutional ownership and monitoring: Evidence from financial misreporting显示文摘 | Natasha Burns Simi Kedia Marc Lipson | 2010 | Journal of Corporate Finance2010，，4： | 2 |
| 7 | International Outsourcing of Services:A Partnership Model显示文摘 | Kedia B L Lahiri S | 2007 | Journal of International Management2007，13，1： | 1 |
| 8 | Corporate Governance and Market Valuation of Capital and RD Investments显示文摘 | Chung K Wright P Kedia B | 2003 | Review of Finan- cial Economics2003，，12： | 1 |
| 9 | Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study显示文摘 | Patel K Kedia M Bajpai D | 2007 | Clin Pharmacol2007，7，： | 1 |
| 10 | Expression of growth hormonereleasing factor,growth hormone,insulin-like growth factor1 and its binding proteins in human lung显示文摘 | Allen J T Bloor C A Kedia R A | 2000 | Neuropeptides2000，34，2： | 1 |
| 11 | MNE's depen- dence on foreign operations and performance: A study of MNEs from the 'Triad' regions显示文摘 | Harveston P D Kedia B L Francis J D | 1999 | International Busi- ness Review1999，8，3： | 1 |
| 12 | Treatment of erectile dysfunction after radical prostatectomy with sildenafl citrate (Viagra)显示文摘 | Zippe CD Kedia AW Kedia K | 1998 | Urology1998，52，6： | 1 |
| 13 | Performance impact of employee stock options显示文摘 | Kedia S Mozumdar A | 2002 | 2002，，： | 1 |
| 14 | International Outsourcing of Services:A Partnership Model显示文摘 | Kedia B.L Lahiri S | | 0，，13： | 1 |
| 15 | Effectiveness and efficiency of cross - border knowledge transfer: an empirical examination显示文摘 | PEREZ-NORDTVEDT L KEDIA B L DATTA D K | 2008 | Journal of Manage- ment Studies2008，45，4： | 1 |
| 16 | Cultural variations in the cross border transfer of organizational knowledge:An integrative framework 显示文摘 | Bhagat R S Kedia B L Harveston P D | 2002 | Academy of Management Review2002，27，2： | 1 |
| 17 | The Impact of Performance-Based Compensation on Misreporting 显示文摘 | Bums N Kedia S | 2006 | Joumal of Financial Economics2006，，79： | 1 |
| 18 | Endoscopic Ultrasound-Guided Biliary Drainage: An Update显示文摘 | Nikhil A. Kumta Prashant Kedia Michel Kahaleh | 2014 | Current Treatment Options in Gastroenterology2014，，2： | 1 |
| 19 | Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study显示文摘 | Banshi Saboo Gundam Reddy Subhashchander Juneja Ashok Kedia Pravin Manjrekar Rahul Rathod | 2015 | Indian Journal of Endocrinology and Metabolism2015，，1： | 1 |
| 20 | Addressing thechallenge of optimum polyhydroxyalkanoate harvesting :monitoring real time process kinetics and biopolymer accumulationusing dielectric spectroscopy 显示文摘 | Kedia G Passanha P Dinsdale R M ef al | 2013 | Bioresource Technology2013，134，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员